IntraBio is a biopharmaceutical company founded in 2015 to discover, develop, and commercialize novel treatments for rare and common neurodegenerative diseases with high unmet medical needs.

Our work leverages the expertise of our founding scientific researchers from the University of Oxford and the University of Munich, and translates their pioneer research in the fields of lysosomal biology, autophagy, and neurology, into orphan drugs and treatments that significantly help to improve the lives of patients, their caregivers, and families.

Our Scientists

IntraBio is a global leader in discovering and developing small molecule drugs that modulate lysosomal function and intracellular calcium signaling.

IntraBio’s platform has broad applicability to rare and common neurological disorders, lysosomal storage disorders (LSDs), and inflammatory diseases. Our leading compounds, IB1000s, are a series of orally administered, modified amino-acid analogs that are well tolerated and have an excellent safety profile. IB1000s have been observed to normalize neuronal membrane potential, regulate intracellular ion signaling, and interact with nutrient-sensing pathways.

Our Publications

IntraBio’s drug-candidates are currently being trialed in 18 different indications (observational, Phase II, and a Phase II/III).

Based on the promising findings from Phase II Observational Studies with its leading compound IB1000, IntraBio is now in the process of applying for multi-national, randomized, placebo-controlled clinical trials for the treatment of patients with Niemann-Pick type C, Tay-Sachs disease, and subtypes of Cerebellar Ataxia. The proposed study will have multiple clinical sites in Europe and the US.  Enrollment is intended to commence in 2018.


Clinical Programs